Below are the financial statements of Ultragenyx Pharmaceutical, including the income statement and balance sheet for the company's latest fiscal year. All figures are accurate, verifiable, and fully traceable to the original annual filing where disclosed.
| All figures in millions of USD | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenues | — | — | — |
| Product sales | 285.42a | 180.41a | 118.93a |
| Royalty revenue | 274.82a | 182.65a | 21.69a |
| Collaboration and license | 0a | 71.18a | 222.71a |
| Total revenues | 560.23a | 434.25a | 363.33a |
| Operating expenses | — | — | — |
| Cost of sales | -76.73a | -45.21a | -28.32a |
| Research and development | -697.87a | -648.45a | -705.79a |
| Selling, general and administrative | -321.61a | -309.8a | -278.14a |
| Total operating expenses | -1,096.2a | -1,003.46a | -1,012.25a |
| Loss from operations | -535.97a | -569.21a | -648.92a |
| Interest income | 36.51a | 26.69a | 11.07a |
| Change in fair value of equity investments | -1.12a | 0.4a | -19.3a |
| Non-cash interest expense on liabilities for sales of future royalties | -63.04a | -66a | -43.02a |
| Other expense | -3.96a | -0.34a | -1.57a |
| Loss before income taxes | -567.59a | -608.46a | -701.73a |
| (Provision for) benefit from income taxes | -1.6a | 1.83a | -5.7a |
| Net loss | -569.18a | -606.64a | -707.42a |
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Ultragenyx Pharmaceutical’s data sources below and access millions more through our Disclosure Search.
Sign up for Tracenable and access millions of corporate disclosures, including annual reports and sustainability filings from global companies, completely free of charge.